|
Getting your Trinity Audio player ready...
|
Hong Kong Science and Technology Parks Corporation (HKSTP) and a China-based pharmaceutical company have unveiled the Simcere ‘Hong Kong Collaborative Innovation Center’ inauguration at the Hong Kong Science Park.
The alliance aims to harness Hong Kong’s robust scientific research capabilities, its wealth of talent, and global connectivity to bolster the city’s proficiency in the research and development (R&D) and translation of cutting-edge pharmaceuticals. The collaborative efforts aspire to contribute significantly to pharmaceutical innovation not only within the Greater Bay Area (GBA) but also on a national scale.
The Chief Corporate Development Officer of HKSTP expressed optimism about the collaboration. He stated that the company is anticipated to provide a significant boost to the biomedical industry, creating additional prospects for collaboration and innovation. With steadfast government support, expectations are high for accelerated growth in the biomedical sector over the next five years.
Meanwhile, the Chief Investment Officer of the pharmaceutical company emphasised the strategic significance of the new centre, stating that it is poised to capitalise on Hong Kong’s distinctive strengths, including its connectivity with the Greater Bay Area, formidable scientific research capabilities, ample talent reservoir, and access to the international capital market. Supported by robust policies, the centre aims to expedite its pipelines both within Hong Kong and in the global market.
The partnering, recognised as an innovation-driven, full-value chain pharmaceutical company, made its debut on the Hong Kong Stock Exchange (HKEX) in 2020. It subsequently earned distinction as one of the first strategic enterprises of the Office for Attracting Strategic Enterprises (OASES) in October 2023. Beyond its presence in Hong Kong, the company has established four additional innovation centres in key locations, namely Shanghai, Nanjing, Beijing, and Boston.
The centre’s inauguration marks a significant milestone in the fusion of technology and innovation within the pharmaceutical domain. This collaboration aligns with Hong Kong’s commitment to becoming a global hub for innovation and technology (I&T). Leveraging the city’s strategic position as a gateway to the Greater Bay Area, the company aims to capitalise on Hong Kong’s strengths, including a robust scientific research ecosystem, a diverse talent pool, and access to international capital markets.
The collaborative venture is poised to accelerate advancements in the research and development of innovative drugs, fostering an environment conducive to technological innovation in the pharmaceutical sector.
The centre signifies a broader commitment to technological progress and scientific breakthroughs in the biomedical industry. With Hong Kong’s proactive stance and the company’s innovative approach, this partnership is expected to catalyse transformative developments in the pharmaceutical landscape, fostering sustainable growth and establishing the region as a frontrunner in pharmaceutical innovation.
As Hong Kong continues to position itself as a hub for I&T, collaborations of this nature are instrumental in driving progress and propelling the city towards a future characterised by groundbreaking advancements in the biomedical and pharmaceutical sectors.
OpenGov Asia earlier reported that HKSTP and a China-based battery manufacturing company entered into a Memorandum of Understanding (MoU) to establish the CATL Research and Development (R&D) Centre at Hong Kong Science Park.
This initiative is marked by CATL’s substantial investment of no less than HK$1.2 billion and its ambitious plan to recruit 500 skilled R&D professionals. The overarching goal is to propel innovation in new energy technologies, nurture local talent, and expand market reach, catalysing sustainable development in Hong Kong.
